Comparative Pharmacology
Head-to-head clinical analysis: ISOVUE 200 versus ISOVUE M 300.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOVUE 200 versus ISOVUE M 300.
ISOVUE-200 vs ISOVUE-M 300
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast medium that attenuates X-rays, providing radiographic contrast by increasing the density of blood vessels and tissues.
Iopamidol is a nonionic, low-osmolality iodinated contrast agent that attenuates X-rays by increasing the density of tissues, thereby enhancing the visibility of vascular structures and organs during imaging procedures. It acts by absorbing X-rays due to the high atomic number of iodine.
Intravenous administration of 1.0-2.0 mL/kg (200 mg iodine/mL) for computed tomography; intra-arterial doses vary by procedure, typically 5-80 mL total. Maximum recommended dose: 2.0 mL/kg.
1.0-2.0 mL/kg intravenous bolus for CT imaging up to a total of 150 mL per procedure; intra-arterial dosing varies by procedure, typical adult dose 30-60 mL per injection.
None Documented
None Documented
2 hours in normal renal function; prolongs up to 30 hours in severe renal impairment. Closely correlates with creatinine clearance.
Terminal elimination half-life: approximately 2 hours (range 1.5–2.5 hours). Normal renal function; prolonged in renal impairment.
Renal: 100% unchanged as iohexol; glomerular filtration with no tubular reabsorption. No biliary/fecal elimination.
Primarily renal excretion via glomerular filtration; unchanged drug: >95% excreted in urine within 24 hours. Biliary/fecal excretion: negligible (<1%).
Category C
Category C
Contrast Media
Contrast Media